Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA

Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.